Investor Presentaiton

A new frontier: CELMOD ADCs to improve efficacy and safety in hematology/solid tumors Causal human biology Combine a clinically validated tumor targeted antibody with a clinically validated tumor cell-biased CELMOD to enhance efficacy and tolerability in hematology/solid tumors Path to clinical proof-of-concept Enhanced efficacy of ADC at lower levels of administered CELMOD Matching modality to mechanism Tumor cytotoxic CELMOD with catalytic activity Tumor targeted antibody to tumor antigen AF Tumor cell Ill Bristol Myers Squibb™ Tumor volume (mm³) 2000- n = 5 1500 1000 500- IV dose 20 HH HH 中 ┤ 25 30 35 Days post-inoculation Vehicle control 10x CELMOD + Ab, unconjugated 1x CELMOD ADC 3x CELMOD ADC 10x CELMOD ADC ADC vs unconjugated components Not for Product Promotional Use 40

View entire presentation